2026-01-18 - Analysis Report
# Eli Lilly and Co. Financial Report

## Company Overview
Eli Lilly and Co is a pharmaceutical company.

## Return Comparison
- Cumulative return of LLY: 266.92%
- Cumulative return of S&P 500 (VOO): 93.36%
- Degree of divergence: 173.56%

## Alpha, Beta Analysis
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 37.0% | 14.3% | 33.0% | 0.7 | 103.7B |
| 2017-2019  | 36.0% | 14.7% | 19.0% | 0.7 | 117.8B |
| 2018-2020  | 30.0% | 20.9% | 10.0% | 0.7 | 151.4B |
| 2019-2021  | 49.0% | 20.9% | 5.0% | 0.7 | 247.6B |
| 2020-2022  | 59.0% | 20.9% | 60.0% | 0.7 | 328.0B |
| 2021-2023  | 116.0% | 18.0% | 115.0% | 0.5 | 522.6B |
| 2022-2024  | 123.0% | 27.0% | 104.0% | 0.6 | 692.1B |
| 2023-2025  | 183.0% | 29.9% | 121.0% | 0.7 | 963.4B |

## Recent Stock Price Fluctuations
- Close: $1,038.40
- Last-Market change: $5.43 (0.53%)
- 5-day SMA: $1,060.57
- 20-day SMA: $1,070.50
- 60-day SMA: $1,009.06

## RSI, PPO Index Indicators
- RSI: 41.58
- PPO: -0.70
- MRI: 0.80
- Risk Level: Medium
- Recent 20-day relative divergence change: -7.30 (-)
- 7-day Rank change: -3 (-)
- 7-day Dynamic Expected Return change: 6.20 (+)
- Expected Return: 58.30%

## Recent News & Significant Events
The company has recently experienced significant fluctuations due to news including:
- Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy?
- Buy The Dip In LLY Stock?
- LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling
- Stocks making the biggest moves midday: Morgan Stanley, Coinbase, Taiwan Semi, Eli Lilly & more
- Eli Lilly: Sell It And Buy Novo Nordisk Instead (NYSE:LLY)
- Eli Lilly shares dip as FDA delays decision on weight-loss pill

## Analyst Opinions
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.70 (~Buy)
- Opinions: 28
- Target Price (avg/high/low): $1,110.79 / $1,500.00 / $770.00

## Recent Earnings Analysis
| Date     | EPS | Revenue |
|----------|-----|---------|
| 2025-10-30 | 6.22 | 17.60 B$ |
| 2025-08-07 | 6.30 | 15.56 B$ |
| 2025-05-01 | 3.07 | 12.73 B$ |
| 2024-10-30 | 1.08 | 11.44 B$ |
| 2025-10-30 | 6.22 | 17.60 B$ |

## Quarterly Financial Information
### Revenue and Profitability
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.60B | 82.91% |
| 2025-06-30 | $15.56B | 84.27% |
| 2025-03-31 | $12.73B | 82.53% |
| 2024-12-31 | $13.53B | 82.24% |
| 2024-09-30 | $11.44B | 81.02% |

### Capital and Profitability
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $23.79B | 23.46% |
| 2025-06-30 | $18.27B | 30.98% |
| 2025-03-31 | $15.76B | 17.50% |
| 2024-12-31 | $14.19B | 31.07% |
| 2024-09-30 | $14.24B | 6.81% |

## Comprehensive Analysis
Due to the high degree of divergence between LLY and VOO, investors should note the significant fluctuations in stock price. Recent news and events, such as the FDA delay on an obesity drug ruling, contribute to uncertainty in the market. With a buy recommendation from analysts and high expected returns, investors may consider long-term investment in the company. However, the MRI indicates a medium-risk level and the company's profit margins have fluctuated in recent quarters. The company's capital and profitability also show signs of improvement, but investors should monitor the progress closely.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.